Abstract
Background and Objectives: The value of glycosylated hemoglobin (HbA1c) as a surrogate marker for the prevention of cardiovascular outcomes on antidiabetic drugs is debated. The 2008 FDA guidance led to multiple large clinical trials to evaluate the effect of new antidiabetic drugs versus placebo on major adverse cardiac events (MACE). The aim of this study was to evaluate the relation between MACE and HbA1c decrease between antidiabetic drug and placebo across the spectrum of cardiovascular outcome trials (CVOT). Methods: In this systematic review, we included randomized controlled trials that compared an antidiabetic drug to placebo in addition to current standard of care with the primary intention of demonstrating cardiovascular safety. We investigated the relationship between MACE decrease on antidiabetic drug and HbA1c reduction on antidiabetic drug using the coefficient correlation. We also studied the effects of potential confounders on MACE decrease. Results: Fourteen eligible trials including 128,149 patients were included, 12,114 of whom experienced MACE. Mean achieved HbA1c absolute reductions on antidiabetic treatment versus placebo varied from 0.29 to 1%. The decrease of MACE on antidiabetic drug was significantly correlated with mean HbA1c reduction (r = 0.88, 95% CI: 0.67–0.96, p < 0.001) and weight loss (r = 0.81, 95% CI: 0.46–0.94, p < 0.001). In a bivariate model including weight loss, only HbA1c reduction remained significantly correlated with the decrease of MACE on antidiabetic drug (p = 0.019). Conclusion: Across CVOT, the decrease in MACE incidence on various antidiabetic drugs is significantly correlated with HbA1c reduction. This meta-analysis supports HbA1c as an appropriate surrogate endpoint for cardiovascular events. Our analysis supports that changes in HbA1c should be taken into account while interpreting effects of new antidiabetic drugs on cardiovascular outcomes.
References
1.
Stratton
IM
, Adler
AI
, Neil
HA
, Matthews
DR
, Manley
SE
, Cull
CA
, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
. BMJ
. 2000
Aug
;321
(7258
):405
–12
.
[PubMed]
0959-81382.
Selvin
E
, Marinopoulos
S
, Berkenblit
G
, Rami
T
, Brancati
FL
, Powe
NR
, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus
. Ann Intern Med
. 2004
Sep
;141
(6
):421
–31
.
[PubMed]
0003-48193.
Nathan
DM
, Cleary
PA
, Backlund
JY
, Genuth
SM
, Lachin
JM
, Orchard
TJ
, et al.; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group
. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
. N Engl J Med
. 2005
Dec
;353
(25
):2643
–53
.
[PubMed]
0028-47934.
Holman
RR
, Sourij
H
, Califf
RM
. Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes
. Lancet
. 2014
Jun
;383
(9933
):2008
–17
.
[PubMed]
0140-67365.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)
. Guidance for industry: diabetes mellitus—evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. http//www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071627.pdf6.
European Medicines Agency
. Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus
. http//www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/06/WC500129256.pdf7.
Lipska
KJ
, Krumholz
HM
. Is hemoglobin A1c the right outcome for studies of diabetes?
JAMA
. 2017
Mar
;317
(10
):1017
–8
.
[PubMed]
0098-74848.
Gerstein
HC
, Miller
ME
, Byington
RP
, Goff
DC
Jr, Bigger
JT
, Buse
JB
, et al.; Action to Control Cardiovascular Risk in Diabetes Study Group
. Effects of intensive glucose lowering in type 2 diabetes
. N Engl J Med
. 2008
Jun
;358
(24
):2545
–59
.
[PubMed]
0028-47939.
Nissen
SE
, Wolski
K
. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
. N Engl J Med
. 2007
Jun
;356
(24
):2457
–71
.
[PubMed]
0028-479310.
Moher
D
, Liberati
A
, Tetzlaff
J
, Altman
DG
; PRISMA Group
. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement
. Ann Intern Med
. 2009
Aug
;151
(4
):264
–9
.
[PubMed]
0003-481911.
Jadad
AR
, Moore
RA
, Carroll
D
, Jenkinson
C
, Reynolds
DJ
, Gavaghan
DJ
, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary?
Control Clin Trials
. 1996
Feb
;17
(1
):1
–12
.
[PubMed]
0197-245612.
Scirica
BM
, Bhatt
DL
, Braunwald
E
, Steg
PG
, Davidson
J
, Hirshberg
B
, et al.; SAVOR-TIMI 53 Steering Committee and Investigators
. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
. N Engl J Med
. 2013
Oct
;369
(14
):1317
–26
.
[PubMed]
0028-479313.
White
WB
, Cannon
CP
, Heller
SR
, Nissen
SE
, Bergenstal
RM
, Bakris
GL
, et al.; EXAMINE Investigators
. Alogliptin after acute coronary syndrome in patients with type 2 diabetes
. N Engl J Med
. 2013
Oct
;369
(14
):1327
–35
.
[PubMed]
0028-479314.
Green
JB
, Bethel
MA
, Armstrong
PW
, Buse
JB
, Engel
SS
, Garg
J
, et al.; TECOS Study Group
. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
. N Engl J Med
. 2015
Jul
;373
(3
):232
–42
.
[PubMed]
0028-479315.
Gantz
I
, Chen
M
, Suryawanshi
S
, Ntabadde
C
, Shah
S
, O’Neill
EA
, et al. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus
. Cardiovasc Diabetol
. 2017
Sep
;16
(1
):112
.
[PubMed]
1475-284016.
Rosenstock
J
, Perkovic
V
, Johansen
OE
, Cooper
ME
, Kahn
SE
, Marx
N
, et al.; CARMELINA Investigators
. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial
. JAMA
. 2019
Jan
;321
(1
):69
–79
.
[PubMed]
0098-748417.
Pfeffer
MA
, Claggett
B
, Diaz
R
, Dickstein
K
, Gerstein
HC
, Køber
LV
, et al.; ELIXA Investigators
. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome
. N Engl J Med
. 2015
Dec
;373
(23
):2247
–57
.
[PubMed]
0028-479318.
Marso
SP
, Daniels
GH
, Brown-Frandsen
K
, Kristensen
P
, Mann
JF
, Nauck
MA
, et al.; LEADER Steering Committee
; LEADER Trial Investigators
. LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes
. N Engl J Med
. 2016
Jul
;375
(4
):311
–22
.
[PubMed]
0028-479319.
Marso
SP
, Bain
SC
, Consoli
A
, Eliaschewitz
FG
, Jódar
E
, Leiter
LA
, et al.; SUSTAIN-6 Investigators
. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes
. N Engl J Med
. 2016
Nov
;375
(19
):1834
–44
.
[PubMed]
0028-479320.
Husain
M
, Birkenfeld
AL
, Donsmark
M
, Dungan
K
, Eliaschewitz
FG
, Franco
DR
, et al.; PIONEER 6 Investigators
. Oral semaglutideand cardiovascular outcomes in patients with type 2 diabetes
. N Engl J Med
. 2019
Aug
;381
(9
):841
–51
.
[PubMed]
0028-479321.
Holman
RR
, Bethel
MA
, Mentz
RJ
, Thompson
VP
, Lokhnygina
Y
, Buse
JB
, et al.; EXSCEL Study Group
. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
. N Engl J Med
. 2017
Sep
;377
(13
):1228
–39
.
[PubMed]
0028-479322.
Hernandez
AF
, Green
JB
, Janmohamed
S
, D’Agostino
RB
Sr, Granger
CB
, Jones
NP
, et al.; Harmony Outcomes committees and investigators
. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
. Lancet
. 2018
Oct
;392
(10157
):1519
–29
.
[PubMed]
0140-673623.
Zinman
B
, Wanner
C
, Lachin
JM
, Fitchett
D
, Bluhmki
E
, Hantel
S
, et al.; EMPA-REG OUTCOME Investigators
. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
. N Engl J Med
. 2015
Nov
;373
(22
):2117
–28
.
[PubMed]
0028-479324.
Neal
B
, Perkovic
V
, Mahaffey
KW
, de Zeeuw
D
, Fulcher
G
, Erondu
N
, et al.; CANVAS Program Collaborative Group
. Canagliflozin and cardiovascular and renal events in type 2 diabetes
. N Engl J Med
. 2017
Aug
;377
(7
):644
–57
.
[PubMed]
0028-479325.
Wiviott
SD
, Raz
I
, Bonaca
MP
, Mosenzon
O
, Kato
ET
, Cahn
A
, et al.; DECLARE–TIMI 58 Investigators
. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
. N Engl J Med
. 2019
Jan
;380
(4
):347
–57
.
[PubMed]
0028-479326.
Intarcia Therapeutics
. A study to evaluate cardiovascular outcomes in patients with type 2 diabetes treated with ITCA 650. In: Clinical-Trials.gov (internet). Available from https//clinical trials.gov/show/NCT0145589627.
Home
PD
, Pocock
SJ
, Beck-Nielsen
H
, Curtis
PS
, Gomis
R
, Hanefeld
M
, et al.; RECORD Study Team
. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
. Lancet
. 2009
Jun
;373
(9681
):2125
–35
.
[PubMed]
0140-673628.
Dormandy
JA
, Charbonnel
B
, Eckland
DJ
, Erdmann
E
, Massi-Benedetti
M
, Moules
IK
, et al.; PROactive Investigators
. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial
. Lancet
. 2005
Oct
;366
(9493
):1279
–89
.
[PubMed]
0140-6736© 2020 S. Karger AG, Basel
2020
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
